The goal of the presented research was to evaluate immunogenicity of the inactivated emulsified avian influenza (AI) type A (H5N1) vaccine that was developed on the basis of epizootically important autogenic AI virus strain A/domestic goose/Pavlodar/1/05 (H5N1) isolated in the epizooty focus in Pavlodarskaya oblast, Republic of Kazakhstan, in 2005. The results of the performed study show high level of vaccine immunogenicity. The vaccine is able to form the immunity for 12 months in 2-months chickens immunized in dose of 0.5 ml. The antihemagglutinating antibodies were detected in 14 days and reached their peak of 1:277 on the 6 th week post vaccination. The vaccination effectiveness is 100% from the 28 th day till the 150 th day post vaccination, then slowly decreases down to the level of 80% till day 360 post immunization (period of observation) that is sufficient for ensuring the safety of the vaccinated birds. Moreover the vaccine has high level of protectiveness demonstrating 100% protection of vaccinated birds on the 28 th day post vaccination and preventing virus shedding from cloaks and tracheas of chickens challenged with a field strain. The results of the study allow concluding that the developed inactivated emulsified AI vaccine of subtype H5 on the basis of the A/domestic goose/Pavlodar/1/05 (H5N1) possesses high protective ability and long-term immunogenicity.